Tag Archive for: Parkinson’s

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

/in

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York. Read […]

Read more

Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson’s Research Supports Development of Disease Modifying Therapy for Parkinson’s Disease

/in

Copenhagen, Denmark and Boston, US, 11th October 2022 – Muna Therapeutics (Muna), a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease and other neurodegenerative disorders, announced today that it has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).  Read more…

Read more

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

/in

Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the study of its clinical stage O-GlcNAcase (OGA) […]

Read more